Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2024-09-20 | 2024-10-04 | 238239 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Actual shortage | 2024-11-29 | 2025-02-06 | 244209 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2024-03-08 | 2024-05-10 | 221729 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2024-05-03 | 2024-05-17 | 227085 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2017-07-26 | 2018-03-27 | 17322 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2019-06-05 | 2019-10-07 | 85610 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2019-07-03 | 2019-10-07 | 88360 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2017-09-04 | 2019-10-15 | 20900 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-01-22 | 36947 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-03-27 | 36949 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2022-11-27 | 2023-03-09 | 175898 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Actual shortage | 2025-01-23 | 2025-02-06 | 248492 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Actual shortage | 2025-03-20 | 2025-03-20 | 253075 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Actual shortage | 2025-02-13 | 2025-02-13 | 250310 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2023-07-21 | 2024-01-05 | 199518 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2021-07-05 | 2021-12-03 | 141854 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2021-12-03 | 2021-12-13 | 150440 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |